Vertex Pharmaceuticals Inc. (VRTX)

155.14
0.53 0.34
NASDAQ : Health Technology
Prev Close 155.67
Open 155.49
Day Low/High 154.13 / 157.41
52 Wk Low/High 113.66 / 178.25
Volume 697.45K
Avg Volume 1.71M
Exchange NASDAQ
Shares Outstanding 254.88M
Market Cap 40.45B
EPS 1.10
P/E Ratio 152.59
Div & Yield N.A. (N.A)

Latest News

Trying the Long Side of Vertex's Stock Again

Trying the Long Side of Vertex's Stock Again

After pharmaceutical company breaks out, charts suggest now is the time to go back in.

Vertex To Present At The Cowen Healthcare Conference On March 13

Vertex To Present At The Cowen Healthcare Conference On March 13

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GTLS, JWN, SBLK, SSW, VRTX Downgrades: ACU, AFH, BKS, CRAY, MATX, MEI, NYLD.A, OPHT Initiations: WAAS Read on to get TheStreet Quant Ratings' detailed report:

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

VX-659 Phase 3 Clinical Trial Program Overview

VX-659 Phase 3 Clinical Trial Program Overview

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating a Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic...

Vertex Appoints Reshma Kewalramani, M.D., As Chief Medical Officer

Vertex Appoints Reshma Kewalramani, M.D., As Chief Medical Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Reshma Kewalramani, M.

Vertex Initiates First Phase 3 Study Of VX-659, Tezacaftor And Ivacaftor As A Triple Combination Regimen For People With Cystic Fibrosis

Vertex Initiates First Phase 3 Study Of VX-659, Tezacaftor And Ivacaftor As A Triple Combination Regimen For People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with...

Vertex Announces Treatment With The NaV1.8 Inhibitor VX-150 Showed Significant Relief Of Acute Pain In Phase 2 Study

Vertex Announces Treatment With The NaV1.8 Inhibitor VX-150 Showed Significant Relief Of Acute Pain In Phase 2 Study

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results of a Phase 2 study of the NaV1.

SYMDEKO (Photo: Business Wire)

SYMDEKO (Photo: Business Wire)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination...

Vertex Reports Full-Year And Fourth-Quarter 2017 Financial Results

Vertex Reports Full-Year And Fourth-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2017.

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Selects Two Next-Generation Correctors, VX-659 And VX-445, To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens For People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination...

Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation

Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted extension of the Marketing Authorization for ORKAMBI ® (lumacaftor/ivacaftor), the first medicine to...

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Feed the Beast: Cramer's 'Mad Money' Recap (Thursday 1/4/18)

Jim Cramer says this beast of a bull market is getting a steady diet of healthful sector opportunities.

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Look no further than the top 10 winners in the S&P 500 and you will see just what I mean.

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth-Quarter And Full-Year 2017 Financial Results

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth-Quarter And Full-Year 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

Dow Jumps After Fed Rate Hike, Posts New Record for Fourth Straight Day

The Dow jumped 80 points on Wednesday, while the S&P 500 declined slightly.

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting

Dow, S&P 500 on Track to Extend Winning Streaks to 5 Days Before Fed Meeting

The Dow and S&P 500 are on track to close higher for a fifth straight day.

Stock Futures Up Slightly, Dollar Drifts as Jones Stuns Moore in Alabama

Stock Futures Up Slightly, Dollar Drifts as Jones Stuns Moore in Alabama

A surprise win for Democrat Doug Jones in Alabama's special Senate election has the dollar on the back foot and investors in a cautious mood ahead of the final Fed meeting of the year.

Vertex Pharmaceuticals Could Be Bought Out for $205 in 2018: Deutsche Bank

Vertex Pharmaceuticals Could Be Bought Out for $205 in 2018: Deutsche Bank

Deutsche Bank said "chances of a Vertex takeout are as good as at any point in the company's history."

4 Signs the Bull Market in Stocks Remains Incredibly Strong

4 Signs the Bull Market in Stocks Remains Incredibly Strong

Growth is here to stay, and value is for more than just the old strongholds.

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex And CRISPR Therapeutics To Co-Develop And Co-Commercialize CTX001 As CRISPR/Cas9 Gene Edited Treatment For Sickle Cell Disease And ß-Thalassemia

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as...

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO® (ivacaftor) In Children With Cystic Fibrosis Ages 1 To 2 Years

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO® (ivacaftor) In Children With Cystic Fibrosis Ages 1 To 2 Years

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from an open-label Phase 3 study of KALYDECO ® (ivacaftor) in children with cystic fibrosis (CF) ages 1 to 2 years who have one...

16 Amazing Stocks to Trade in This Unstoppable Bull Market

16 Amazing Stocks to Trade in This Unstoppable Bull Market

After a shortened trading week light on volume, the S&P 500 is losing some steam. But Fundstrat says index uptrends 'remain intact' moving toward the New Year.

Vertex Receives CHMP Positive Opinion For ORKAMBI® (lumacaftor/ivacaftor) For The Treatment Of Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation In The European Union

Vertex Receives CHMP Positive Opinion For ORKAMBI® (lumacaftor/ivacaftor) For The Treatment Of Children With Cystic Fibrosis Ages 6-11 With Two Copies Of The F508del Mutation In The European Union

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending extension of the Marketing...

Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Of stocks seeing the biggest gains since the presidential election, only a few owe their success to Trump.

Vertex Announces Presentations Of Data At North American Cystic Fibrosis Conference That Demonstrate Important Progress Toward Goal Of Helping All People With CF

Vertex Announces Presentations Of Data At North American Cystic Fibrosis Conference That Demonstrate Important Progress Toward Goal Of Helping All People With CF

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced presentations of data at the Annual North American Cystic Fibrosis Conference (NACFC), November 2 to 4, 2017, in Indianapolis, from across the...

TheStreet Quant Rating: B- (Buy)